Biosafety

Announcements

Revisions to the approved IBC Policy June 20, 2023 IBC meeting:

The 国产短视频Institutional Biosafety Committee (IBC) has approved a new policy regarding the Continuing Reviews (CRs) of IBC protocols. The new policy will eliminate the requirement for submission of CRs for most IBC protocols. The new policy is available in IBC Policy Manual (PDF).

The changes to the policy are as follows:

CR requirement:

  1. Most IBC protocols for the use of infectious materials/recombinant DNA(rDNA) will no longer require CRs.
  2. There is no change to the CR policy for IBC protocols involving the administration of rDNA to human research subjects (clinical trials). They will continue to require CRs at 6 months or one year dependent on the IBC risk assessment.

Approval period:

  1. Infectious materials and non-exempt rDNA IBC protocols will be approved for a three-year period with no CR requirement. These protocols will be required to be renewed at the three year expiration if the project will continue.
  2. Exempt rDNA use or storage of agents IBC protocols for the use of will be approved for a five-year period with no CR requirement. These protocols will be required to be renewed at the five year expiration if the project will continue.

Biosafety Announcements Archive (2014 - 2018)